The effect of high energy magnetic field therapies for attachment tendinopathies and bursitis on pain and the inflammatory modulator HSP 70.

Not Applicable

• Conditions: M77.1; M77.9; Other disorders of synovium and tendon; Bursitis of hand; Pseudosarcomatous fibromatosis; Rotator cuff syndrome; M77.0; M67; M62.65; M70.1

• Registration Number: DRKS00031321
• Lead Sponsor: Institut für Bewegungswissenschaft Arbeitsbereich Sport- und Bewegungsmedizin

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2023-02-21
• Study Completion: 2023-03-18
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

Long-standing muscle-tendon complaints (e.g. patella-tip syndrome jumper's knee, Achilles tendon complaints, tennis elbow or golfer's elbow)

Exclusion Criteria

- Heart/brain pacemakers
- cochlear implants
- other endoprosthetic implants
- Pregnancy (outpatient pregnancy test/ sonographic control)
- cancer diseases
- Diseases affecting pain perception (e.g. polyneuropathy)

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The primary outcome will be the pain pressure threshold (algometry) at 5 measurement time points (t0: immediately before, t1: immediately after, t2: 1 hour after, t3: 1 day after, t4: 1 week after the intervention). For this purpose we use the Wagner FDX 100 algometer from Wagner Instruments (S/N 1909600515, USA).

Secondary Outcome Measures

Name	Time	Method
The serum concentration of HSP-70 is determined at 4 measurement time points (t0: immediately before, t2: 1 hour after, t3: 1 day after, t4: 1 week after the intervention). For this purpose, we collect 4 blood samples at the aforementioned time points and determine the serum concentration of HSP-70